Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET

Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268 healthy c...

Full description

Saved in:
Bibliographic Details
Published inAnnals of clinical and translational neurology Vol. 6; no. 6; pp. 1113 - 1120
Main Authors Iaccarino, Leonardo, Sala, Arianna, Perani, Daniela
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.06.2019
Wiley
John Wiley and Sons Inc
Subjects
Accuracy
Aged
Aged, 80 and over
Alzheimer Disease - diagnostic imaging
Alzheimer's disease
Amyloid beta-Peptides - metabolism
Biomarkers
Biomarkers - metabolism
Brain
Brain research
Brief Communication
Brief Communications
Clinical trials
Clinical Trials as Topic
Cognitive ability
Cognitive Dysfunction - diagnostic imaging
Dementia
Dementia - diagnosis
Disease Progression
Female
Fluorodeoxyglucose F18 - metabolism
Healthy Volunteers
Human health sciences
Humans
Magnetic Resonance Imaging
Male
Medical imaging
Middle Aged
Neurodegeneration
Pharmaceutical industry
Positron-Emission Tomography - methods
R&D
Radiologie, médecine & imagerie nucléaire
Radiology, nuclear medicine & imaging
Research & development
Sciences de la santé humaine
Southern California
United States > US
Online AccessGet full text
ISSN2328-9503
2328-9503
DOI10.1002/acn3.782

Cover

More Information
Summary:Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268 healthy controls and N = 519 mild cognitive impairment subjects. Despite being a significant risk factor, amyloid positivity was not associated with clinical progression in the majority (≥60%) of subjects. Notably, a negative [18F]FDG‐PET scan at baseline strongly predicted clinical stability with high negative predictive values (>0.80) for both groups. We suggest [18F]FDG‐PET brain metabolism or other neurodegeneration measures should be coupled to amyloid‐PET to exclude clinically stable individuals from clinical trials.
Bibliography:Ministero della Salute, grant number: NET‐2011‐02346784, CTN01_00177_165430; FP7 Health, grant number: 2758850; National Institutes of Health, grant number: U01 AG024904.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
scopus-id:2-s2.0-85076289713
Data used in preparation of this article were also obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.782